Corporate Travel Management Ltd (ASX: CTD) shares have finally returned to the ASX, and investors have not held back.

The Corporate Travel share price is down 80.40% to $3.15 in early Thursday trade after the company’s long suspension was lifted.

The stock last traded at $16.07 before it was suspended in August 2025, and a lot has gone wrong since then.

Investors are now showing exactly what they think of it.

Shares have traded as low as $2.81 this morning.

Why were Corporate Travel shares suspended?

The problems started in the company’s UK business, where some serious accounting issues were uncovered.

A KPMG review found revenue had been recognised incorrectly on large customer contracts completed between 2021 and 2023. That included around GBP 45.4 million sitting in a “Concluded Customer Contracts” account that should not have been recognised as revenue.

Corporate Travel later said it could restate as much as GBP 58.2 million across FY23 and FY24, with another GBP 19.4 million of adjustments flagged for FY25.

Since then, the company has spent much of the past year sorting through the mess, including refunding customers, restating its accounts and making changes to its financial controls.

There’s been some progress, with Corporate Travel saying this week that around 78% of customer refunds have either been agreed or are close to being finalised.

What did the FY26 result show?

Despite everything that has happened, there were some signs the underlying business moved in the right direction during FY26.

Revenue and other income rose 4% to $669.9 million, while underlying EBITDA jumped 36% to $113.6 million.

Corporate Travel also returned to profit, posting net profit after tax (NPAT) of $17.7 million. Keep in mind, that’s a big turnaround from the $348.5 million loss recorded a year earlier.

Activity also picked up, with transaction volumes rising 13% to 18.3 million and total transaction value (TTV) increasing 2% to $9.8 billion.

Europe was one of the better-performing regions. Revenue climbed 34% to $113.7 million, while underlying EBITDA improved to $24.7 million from a $1.2 million loss.

But the balance sheet is still one area investors are watching closely.

Corporate Travel ended FY26 with $106.9 million in cash and has since secured a $175 million funding package to help finish the remediation work and support the business.

What happens next?

Management said trading in the first month of FY27 was broadly in line with expectations, although the early numbers were mixed.

July transaction volumes rose to around 1.6 million from 1.5 million a year earlier, while revenue slipped to $53.3 million from $58.3 million.

Corporate Travel has also secured $178 million of new business on a TTV basis so far in FY27.

And there was also some good news from the Australian Government review, which found no signs of widespread or systemic overcharging.

Still, the company has a lot of work ahead of it after what has been a shocking period for shareholders.

The post Warning: Corporate Travel shares have crashed 80%. What on earth just happened? appeared first on The Motley Fool Australia.

More reading

• Corporate Travel Management shares resume trading after FY26 report
• Corporate Travel Management swings to profit as earnings jump in FY26
• Corporate Travel Management reports FY25 and 1HY26 earnings
• Corporate Travel Management secures new funding and updates on FY25 and FY26 earnings
• Corporate Travel Management updates UK remediation progress and settlement terms

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Corporate Travel Management. The Motley Fool Australia has positions in and has recommended Corporate Travel Management. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

A busy day is set to be underway on the stock market, with several well-known S&P/ASX 200 Index (ASX: XJO) companies trading ex-dividend today.

The list includes BHP Group Ltd (ASX: BHP), Woodside Energy Group Ltd (ASX: WDS) and Coles Group Ltd (ASX: COL), along with another four other ASX 200 shares.

Combined, the dividends are worth around 31 points on the ASX 200, according to IG.

That could make some of the share price moves look worse than they really are on Thursday.

Let’s take a closer look.

BHP, Woodside and Coles lead the way

BHP is easily the largest company on today’s list.

The mining giant closed Wednesday at $64.65 and is trading ex-dividend for $1.39 per share, fully franked.

That means anyone buying BHP shares from today will not receive the payment, which is due to eligible shareholders on 23 September.

Woodside is another heavyweight going ex-dividend.

Its shares finished yesterday at $33.08 and are now trading without a 79.51-cent fully franked dividend attached. Woodside is due to pay shareholders on 25 September.

Coles closed Wednesday at $23.89 and has a 37-cent fully franked dividend coming off its share price today. The supermarket giant will make the payment on 22 September.

However, with all three carrying such huge index weightings, going ex-dividend is likely to put some pressure on the ASX 200 today.

4 more ASX 200 shares to watch

There are also several other payouts investors should be aware of.

Amcor Plc (ASX: AMC) closed at $64.15 and is trading ex-dividend for 92 cents per share. Unlike the other larger payouts today, the Amcor dividend is unfranked.

Ramsay Health Care Ltd (ASX: RHC) finished Wednesday at $52.38 and is going ex-dividend for 48.5 cents per share, fully franked.

Meanwhile, NIB Holdings Ltd (ASX: NHF) closed at $6.97 and is trading without its 21-cent fully franked dividend.

Rounding out the group is Sigma Healthcare Ltd (ASX: SIG), which closed at $2.71. Its latest dividend is 2 cents per share, also fully franked.

Sigma shareholders are due to receive their payment on 22 September, Ramsay on 24 September and NIB on 7 October.

What investors should keep in mind

There is a fair bit going on with the index today, so the headline move may not tell the full story.

BHP, Woodside and Coles are all large enough to have an impact, and having all 3 go ex-dividend on the same day adds some extra weight.

So, if the ASX 200 looks a bit weak, the dividend effect is worth factoring in.

The post Own BHP, Woodside or Coles shares? Here’s what investors should know appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• The average superannuation balance for 45-year-olds in Australia in FY26. How does yours compare?
• How much is needed in superannuation for $1,000 in weekly passive income?
• BHP shares are falling – is it time to take profits?
• Here’s how Fortescue, Rio Tinto and BHP shares stacked up in August

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Amcor Plc and NIB Holdings. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sonic Healthcare Ltd (ASX: SHL) shares have slipped further into the red in Thursday morning trade.

At the time of writing, the shares are down around another 1%, and they’re trading close to a decade low, at $18.57 each.

Today’s slide means the shares have now crashed 21% over the past two weeks, and they’re now 17% lower for the year to date.

What has happened to Sonic Healthcare shares?

After a strong sell-off earlier this year, ASX healthcare shares came back into favour recently. 

Ahead of the share price crash two weeks ago, Sonic Healthcare shares had rebounded around 28% from a 10-year low in Mid-May. And its shares didn’t move in isolation, either. Australian healthcare stocks have staged a major recovery over the past month, with the healthcare index rising around 18% over the past month.

But amid the sector recovery, Sonic Healthcare reported its results on the 20th of August, and it sent investors into a tailspin.

For FY26, the company reported a 13% increase in revenue and a 11% increase in underlying EBITDA to $1.933 billion. It also reported a 17% increase in underlying NPAT and strong organic revenue growth of 5%.

The result looks good on face value and was broadly in line with expectations, but there were concerns about the strength of Sonic Healthcare’s outlook and about margin pressure overseas.

At the time of its results announcement, the company said it expects continued organic growth across its major markets. This is expected to be underpinned by demand for personalised and preventative healthcare. 

The company also provided EBITDA guidance in the range of $1.95 billion to $2.03 billion (in constant currency). This excludes costs from its IT transformation program. 

It also flagged some earnings headwinds from regulatory changes in Switzerland and a slower ramp-up of profit from its large UK NHS contract.

Ahead of the result, analysts had pinpointed margin recovery as the key part of the investment case. So it looks like Sonic Healthcare’s outlook spooked investors, and many quickly sold up their shares and fled the stock.

So, what do the experts think?

Are the ASX healthcare shares a buy, sell, or hold now?

According to TradingView data, the majority of analysts are neutral about the outlook for Sonic Healthcare shares going forward.

Out of 18 analysts, 10 now have a hold rating. The remaining eight ratings are split between buy/strong buy and sell/strong sell.

The average $22.11 target price, however, does imply a potential 19% upside after the latest sell-off. Even the minimum $19.60 target price suggests the shares could climb another 5%, at the time of writing.

Bell Potter confirmed its buy rating on Sonic Healthcare shares shortly following the results announcement, but shaved its target price to $27.50. The broker said the result was in guidance. But added that the rebounding share price is mostly the result of a broad sector rebound.

The post Sonic Healthcare shares crash 21%: What on earth is going on? appeared first on The Motley Fool Australia.

More reading

• Why these ASX shares are worth watching closely today
• Could this 7%-yielding ASX healthcare share be a growth winner?
• Why this ASX healthcare share is a retiree’s dream for FY27
• Why I think these boring ASX shares could build serious wealth
• 37 ASX shares going ex-dividend next week

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.